Overview
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder characterized by the presence of the BCR-ABL fusion gene, which arises from a reciprocal translocation between chromosomes 9 and 22, forming the Philadelphia chromosome. This fusion gene encodes a constitutively active tyrosine kinase that drives uncontrolled cell proliferation.
Imatinib is a first-generation tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL protein and is widely used as first-line therapy in CML. Although most patients respond well initially, a significant proportion develop resistance or intolerance over time. Imatinib Resistance Mutation Analysis (IRMA), also known as ABL kinase domain mutation analysis, is performed to identify mutations responsible for resistance and to guide alternative treatment strategies.
Imatinib Resistance in CML
Resistance to imatinib is a major clinical challenge in the long-term management of CML. Resistance may be classified into two broad categories.
Primary resistance refers to the lack of optimal response to imatinib from the beginning of therapy. Acquired resistance occurs when a patient initially responds to treatment but later loses response despite continued therapy.
Multiple mechanisms contribute to resistance, including BCR-ABL gene amplification, altered drug transport, and most importantly, mutations in the ABL kinase domain. These mutations interfere with imatinib binding and are the most common cause of resistance in CML patients.
Role of IRMA
The IRMA test plays a crucial role in identifying the molecular basis of imatinib resistance. It is designed to detect more than 90 known and novel mutations in the ABL kinase domain of the Philadelphia chromosome.
These mutations include clinically significant alterations such as T315I and P-loop mutations, which are strongly associated with resistance to imatinib. Detection of these mutations allows clinicians to understand why therapy has failed and to select the most appropriate alternative TKI.
Common BCR-ABL Mutations
Different mutations in the ABL kinase domain show variable resistance patterns and sensitivity to alternative TKIs. The T315I mutation confers high-level resistance to imatinib, dasatinib, and nilotinib but remains sensitive to ponatinib.
E255K and E255V mutations cause partial resistance to imatinib and may respond to dasatinib or nilotinib. The Y253H mutation leads to reduced response to imatinib but may still respond to dasatinib. Mutations such as F359V and F359I show reduced imatinib sensitivity and may respond to dasatinib or bosutinib. The M351T mutation usually causes low-level resistance and often responds well to second-generation TKIs.
Clinical Significance of IRMA
IRMA testing has significant therapeutic implications. When imatinib resistance is detected, second-generation TKIs such as nilotinib can be used as alternative treatment options.
Nilotinib inhibits the BCR-ABL tyrosine kinase more potently than imatinib and binds with higher affinity to the ATP-binding site. This allows it to overcome resistance caused by many ABL kinase domain mutations. Clinical studies have shown that patients treated with nilotinib experience earlier and higher response rates and a lower risk of progression to accelerated phase or blast crisis compared to those treated with imatinib.
Indications for IRMA Testing
IRMA testing is indicated in CML patients who fail to respond adequately to imatinib therapy. It is also recommended when there is evidence of disease progression despite ongoing treatment.
The test is primarily performed to detect mutations in the BCR-ABL gene that explain resistance and help guide further therapeutic decisions.
Sample Collection
Samples for IRMA testing can be obtained from bone marrow or peripheral blood. Bone marrow aspiration requires a minimum volume of 2.5 mL.
Peripheral blood samples are collected in EDTA (lavender-capped) tubes, with a total volume of 6.0 to 9.0 mL, usually divided into multiple tubes. Specimens should be kept cold during transit but must not be shipped on dry ice.
Transportation and Storage
Proper storage and transportation are essential to prevent degradation of nucleic acids. Samples should be stored and transported at ambient temperature and sent to the laboratory within 8 hours of collection.
If bone marrow aspiration is performed, bone marrow smears should also be submitted. A duly completed surgical pathology request form must accompany the specimen.
Assay Methods
Mutation detection can be performed using conventional Sanger sequencing or next-generation sequencing (NGS). Sanger sequencing has long been considered the gold standard but has limited sensitivity, as it cannot detect mutations present in less than 15–20% of transcripts.
NGS offers higher sensitivity and can detect low-level and emerging mutations much earlier. This allows clinicians to identify resistance months before clinical failure becomes apparent, enabling timely modification of therapy.
Advantages of IRMA
IRMA enables early detection of imatinib resistance and supports targeted therapy adjustment. By identifying specific resistance mutations, clinicians can select the most effective alternative TKI.
Early intervention based on IRMA results improves progression-free survival and helps prevent disease advancement to accelerated or blast phases, making it an essential tool in modern CML management.
